Moffitt Cancer Center and Virogen Biotechnology Forge Groundbreaking Partnership to Accelerate Oncology and Immunotherapy Innovations

Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology Inc., a clinical-stage biotechnology company, announced a groundbreaking strategic partnership today. This collaboration aims to propel the development of Virogen’s cutting-edge fusion protein, VG712 (Resimmune), addressing significant unmet needs in oncology and immunotherapy. 

Read More